0001104659-21-082070.txt : 20210616
0001104659-21-082070.hdr.sgml : 20210616
20210616170726
ACCESSION NUMBER: 0001104659-21-082070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210614
FILED AS OF DATE: 20210616
DATE AS OF CHANGE: 20210616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bellemin Jean-Marc
CENTRAL INDEX KEY: 0001754253
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 211022250
MAIL ADDRESS:
STREET 1: C/O GRITSTONE ONCOLOGY, INC.
STREET 2: 5858 HORTON STREET, SUITE 210
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm2119923-4_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-14
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001754253
Bellemin Jean-Marc
C/O IOVANCE BIOTHERAPEUTICS, INC.
999 SKYWAY ROAD, SUITE 150
SAN CARLOS
CA
94070
0
1
0
0
Chief Financial Officer
Restricted Stock Units
2021-06-14
4
A
0
37700
0.00
A
Common stock
37700
37700
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022.
/s/ Jean-Marc Bellemin
2021-06-16